Davide Bolignano

Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease

Davide Bolignano, Antonio Lacquaniti, Giuseppe Coppolino et al. · Clinical Journal of the American Society of Nephrology · 2009 · 556 citations

Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial

Fabio Manfredini, Francesca Mallamaci, Graziella D’Arrigo et al. · Journal of the American Society of Nephrology · 2016 · 395 citations · Full text

Randomized Clinical Trial, Physical Activity, Dialysis Therapy +23

Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Anne Blanchard, Detlef Böckenhauer, Davide Bolignano et al. · Kidney International · 2016 · 344 citations · Full text

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9